Dust mite induces multiple polar T cell axes in human skin

被引:26
作者
Malik, K. [1 ,2 ]
Ungar, B. [1 ,2 ]
Garcet, S. [2 ]
Dutt, R. [1 ]
Dickstein, D. [1 ]
Zheng, X. [2 ]
Xu, H. [1 ]
Estrada, Y. D. [1 ]
Suarez-Farinas, M. [2 ,3 ,4 ,5 ]
Shemer, A. [6 ]
Krueger, J. G. [2 ]
Guttman-Yassky, E. [1 ,2 ,4 ,7 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10021 USA
[3] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
[5] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA
[6] Dept Dermatol, Tel Aviv, Israel
[7] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
allergic contact dermatitis; atopic dermatitis; atopy patch test; house dust mite; psoriasis; HONEY-BEE VENOM; PLACEBO-CONTROLLED TRIAL; RUSH-IMMUNOTHERAPY; SEVERE ANAPHYLAXIS; SYSTEMIC REACTIONS; HYMENOPTERA VENOM; DOUBLE-BLIND; OMALIZUMAB; PRETREATMENT; REDUCTION;
D O I
10.1111/cea.13040
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: House dust mite/HDM atopy patch test/APT elicits positive reactions in a high fraction of atopic dermatitis/AD and healthy individuals. Experimental systems for new-onset/chronic AD are needed to support rapid therapeutic development, particularly since animal models representing human AD are lacking. While HDM APT has been considered to simulate AD, its suitability to model AD's emerging Th2/Th22 phenotype with Th1 and Th17 components is unknown. Objective: To assess whether HDM APT reproduces AD. Methods: Positive HDM APTs (n = 15) from patients with and without AD were evaluated, using genomic and immunohistochemistry studies, against intrapersonal control skin. Results: APT lesions showed higher T cell and dendritic cell infiltrates vs. controls. Seven hundred and forty-three up-and 326 downregulated genes were differentially expressed in HDM APT (fold change > 2 and false discovery rate <0.05), with increased expression of Th2, Th9, Th17/Th22 polar cytokines (i.e. IL-5, IL-13, IL-9, IL-17, IL-22). Conclusion: While HDM caused significant Th2 skewing, it also illustrated differences in Th2 induction and barrier defects; thus, HDM APT does not fully simulate AD. Given its widespread availability and sensitization rates, HDM may potentially be a useful tool that represents select aspects of AD, psoriasis, or contact dermatitis.
引用
收藏
页码:1648 / 1660
页数:13
相关论文
共 26 条
[1]   REDUCTION OF SIDE-EFFECTS FROM RUSH-IMMUNOTHERAPY WITH HONEY-BEE VENOM BY PRETREATMENT WITH TERFENADINE [J].
BERCHTOLD, E ;
MAIBACH, R ;
MULLER, U .
CLINICAL AND EXPERIMENTAL ALLERGY, 1992, 22 (01) :59-65
[2]  
BOUSQUET J, 1988, ANN ALLERGY, V61, P63
[3]   Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial [J].
Brockow, K ;
Kiehn, M ;
Riethmuller, C ;
Vieluf, D ;
Berger, J ;
Ring, J .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (04) :458-463
[4]   Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis [J].
Casale, TB ;
Busse, WW ;
Kline, JN ;
Ballas, ZK ;
Moss, MH ;
Townley, RG ;
Mokhtarani, M ;
Seyfert-Margolis, V ;
Asare, A ;
Bateman, K ;
Deniz, Y .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) :134-140
[5]   Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome [J].
da Silva, Elizabeth Nicole ;
Randall, Katrina Louise .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2013, 1 (06) :687-688
[6]  
Galera C, 2009, J INVEST ALLERG CLIN, V19, P225
[7]   Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy [J].
Goldberg, A ;
Confino-Cohen, R .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (04) :405-410
[8]  
Gomis VS, 2008, J INVEST ALLERG CLIN, V18, P225
[9]   A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy [J].
Hockenhull, J. ;
Elremeli, M. ;
Cherry, M. G. ;
Mahon, J. ;
Lai, M. ;
Darroch, J. ;
Oyee, J. ;
Boland, A. ;
Dickson, R. ;
Dundar, Y. ;
Boyle, R. .
HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (12) :1-+
[10]   Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis [J].
Kontou-Fili, K. ;
Filis, C. I. .
ALLERGY, 2009, 64 (09) :1384-1385